Jun 27, 2022
Javier Szwarcberg, CEO of Spruce Biosciences, is developing a compound to address the needs of patients with classic congenital adrenal hyperplasia, CAH, a rare disease first diagnosed at birth. Only recently have companies started to explore innovative therapies to improve the standard of care discovered in the early...
Developing Small Molecule Compound to Manage Rare Disease Classic Congenital Adrenal Hyperplasia with Javier Szwarcberg Spruce Biosciences TRANSCRIPT
Download PDFJun 27, 2022
Javier Szwarcberg, CEO of Spruce Biosciences, is developing a compound to address the needs of patients with classic congenital adrenal hyperplasia, CAH, a rare disease first diagnosed at birth. Only recently have companies started to explore innovative therapies to improve the standard of care discovered in the early...
First Oral Treatment for Rare Disease Acromegaly with Sheila Frame Amryt Pharma TRANSCRIPT
Download PDFJun 6, 2022
Sheila Frame is the President for the Americas at Amryt Pharma, founded on the belief that rare and ultra-rare diseases were an opportunity to support underserved patients differently than the big pharmaceutical companies could. With the acquisition of Mycapssa, Amryt is changing the treatment for the rare disease...
Jun 6, 2022
Sheila Frame is the President for the Americas at Amryt Pharma, founded on the belief that rare and ultra-rare diseases were an opportunity to support underserved patients differently than the big pharmaceutical companies could. With the acquisition of Mycapssa, Amryt is changing the treatment for the rare disease...
Identifying Biomarkers and Effective Therapies for ALS with Alon Ben-Noon NeuroSense Therapeutics TRANSCRIPT
Download PDFMay 3, 2022
Alon Ben-Noon is the Co-Founder and CEO of NeuroSense Therapeutics, which is working on ALS therapy and other neurodegenerative diseases like Parkinson's and Alzheimer's disease. They are working on a disease-modifying drug PrimeC and have identified a large set of biomarkers that are related to ALS progression and the...